GlobeNewswire by notified

Samsung Bioepis Releases 2024 Sustainability Report, Highlighting Progress in Accessibility and R&D Innovation

  • Report highlights key progress and achievements across three pillars: access to medicines, R&D innovation, and product quality and patient safety
  • 430,000 patients have been treated with Samsung Bioepis’ biosimilars across 40 countries in 2023
  • In 10 countries, our biosimilars have created social impact worth approximately 2.5 trillion KRW (1.9 billion USD) in 2023
  • The company reaffirms its commitment to achieving Net Zero by 2050 as part of the global effort to tackle climate change; company’s first report on Task Force on Climate-Related Financial Disclosures (TCFD) to be released in second half of 2024

INCHEON, Korea, June 25, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today issued its 2024 sustainability report, underscoring its progress toward building more sustainable and socially responsible practices in access to medicines, R&D innovation, and product quality and patient safety.

“In pursuit of our vision ‘Passion for Health’, we ensure that our environmental, social and governance responsibilities are systematically managed. This year’s sustainability report reflects our ongoing efforts to deliver positive social impact to patients while maintaining transparency and accountability in all aspects of our operations,” said Christopher Hansung Ko, President and Chief Executive Officer at Samsung Bioepis. “Through our operations, we make sure that we’re making positive contribution to the communities we serve and also fostering long-term value for all of our stakeholders including patients, communities and governments.”

The annual report provides a comprehensive overview of Samsung Bioepis’ performance and management of the company’s commitment to sustainability, and key highlights of the report are as follows:

1) Access to Medicines: In 2023 alone, Samsung Bioepis’ seven biosimilar medicines have been used to treat approximately 430,000 patients across 40 countries. 2023 witnessed biosimilar launches across several therapeutic areas, including adalimumab biosimilar launch in the United States and ophthalmology and hematology biosimilar launches in Europe. Based on assessment across 10 countries, our biosimilars have been estimated to create 2.5 trillion KRW (1.9 billion USD) social impact by helping healthcare systems achieve cost savings and by improving patients and caregivers quality of life and work productivity.i

2) R&D Innovation: We are continuing to optimize our biosimilar development platform through Quality by Design (QbD), Tollgate Systems, and Failure Modes and Effects Analysis (FMEA). We are able to develop biosimilars more effectively at a faster speed through higher productivity of cell line development, optimization of scale-up system, automation of analysis methods, digitalization of data management, and computerized modeling for process development. In addition, we are expanding R&D into antibody drug conjugates (ADC) and cell and gene therapy (CGT) by collaborating with biotech companies for research and development of drugs to explore new business growth opportunities.

3) Product Quality and Patient Safety: We have implemented a very stringent quality management system which allows us to detect potential quality risks in advance and manage them effectively in a timely manner. This has allowed us to provide biosimilar medicines that are quality-assured from cell line development to commercial manufacturing. As a result, we have not received any warning letter from regulatory agencies, for 35 inspections which were conducted throughout 2021-2023.

In addition, Samsung Bioepis received two ISO certifications: ISO 27001 (Information Security Management System) and ISO 45001 (Occupational Safety & Health Management System) in August 2023, underscoring the company’s commitment to providing healthy and safe workplace environment and ensuring information security. Since 2022, together with Samsung Biologics, Samsung Bioepis is committed to achieving Net Zero by 2050, as part of the global effort to tackle climate change. At the heart of the commitment is achieving net zero carbon emissions (Scope 1 & Scope 2) by converting our direct and indirect energy sources to renewable energy in mid-to-long term.

The company’s report is formulated in the Global Reporting Initiative (GRI) Standards and details activities and achievements that are aligned with the Sustainability Accounting Standards Board (SASB) Standards. Samsung Bioepis’ detailed ESG performance can be found in the full report:

Assessing our ESG Impact

Samsung Bioepis has been conducting a double materiality assessment to assess and prioritize 10 material issues: 1) product responsibility and safety, 2) access to medicines, 3) supply chain ESG risk management, 4) R&D and product innovation, 5) ethics and compliance management, 6) climate change, 7) governance, 8) human resources and talent management, 9) product lifecycle quality management, and 10) ethics for clinical trial and animal testing. These issues are assessed based on both financial and impact materiality, and are being managed based on key metrics and targets set for each issue. We also engage with our stakeholders – customers, employees, suppliers, vendors, investors, shareholders, academic institutions, local communities, governments, media, and trade associations – and incorporate their feedback when assessing the material issues and our ESG performance.

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology and endocrinology. For more information, please visit: and follow us on social media – X, LinkedIn.

Yoon Kim, Nayun Kim,


i 10 countries are the United States (US), Germany, France, Italy, Spain, United Kingdom (UK), Republic of Korea, Canada, Australia, and Brazil.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Iveco Group signs a 150 million euro term loan facility with Cassa Depositi e Prestiti to support investments in research, development and innovation11.6.2024 12:00:00 CEST | Press release

Turin, 11th June 2024. Iveco Group N.V. (EXM: IVG), a global automotive leader active in the Commercial & Specialty Vehicles, Powertrain and related Financial Services arenas, has successfully signed a term loan facility of 150 million euros with Cassa Depositi e Prestiti (CDP), for the creation of new projects in Italy dedicated to research, development and innovation. In detail, through the resources made available by CDP, Iveco Group will develop innovative technologies and architectures in the field of electric propulsion and further develop solutions for autonomous driving, digitalisation and vehicle connectivity aimed at increasing efficiency, safety, driving comfort and productivity. The financed investments, which will have a 5-year amortising profile, will be made by Iveco Group in Italy by the end of 2025. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society. The eight brands are each a

DSV, 1115 - SHARE BUYBACK IN DSV A/S11.6.2024 11:22:17 CEST | Press release

Company Announcement No. 1115 On 24 April 2024, we initiated a share buyback programme, as described in Company Announcement No. 1104. According to the programme, the company will in the period from 24 April 2024 until 23 July 2024 purchase own shares up to a maximum value of DKK 1,000 million, and no more than 1,700,000 shares, corresponding to 0.79% of the share capital at commencement of the programme. The programme has been implemented in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (“MAR”) (save for the rules on share buyback programmes set out in MAR article 5) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour rules. Trading dayNumber of shares bought backAverage transaction priceAmount DKKAccumulated trading for days 1-25478,1001,023.01489,100,86026:3 June 20247,0001,050.597,354,13027:4 June 20245,0001,055.705,278,50028:6 June20243,0001,096.273,288,81029:7 June 20244,0001,106.174,424,68

Landsbankinn hf.: Offering of covered bonds11.6.2024 11:16:36 CEST | Press release

Landsbankinn will offer covered bonds for sale via auction held on Thursday 13 June at 15:00. An inflation-linked series, LBANK CBI 30, will be offered for sale. In connection with the auction, a covered bond exchange offering will take place, where holders of the inflation-linked series LBANK CBI 24 can sell the covered bonds in the series against covered bonds bought in the above-mentioned auction. The clean price of the bonds is predefined at 99,594. Expected settlement date is 20 June 2024. Covered bonds issued by Landsbankinn are rated A+ with stable outlook by S&P Global Ratings. Landsbankinn Capital Markets will manage the auction. For further information, please call +354 410 7330 or email

Relay42 unlocks customer intelligence with a new insights and reporting module, powered by Amazon QuickSight11.6.2024 11:00:00 CEST | Press release

AMSTERDAM, June 11, 2024 (GLOBE NEWSWIRE) -- Relay42, a leading European Customer Data Platform (CDP), is leveraging Amazon QuickSight to power its new real-time customer intelligence, reporting, and dashboard module. Harnessing the breadth and quality of customer data, the new Insights module empowers marketing teams to dive deep into customer behaviors and gain invaluable insights into the performance of their marketing programs across all online, offline, paid, and owned marketing channels. Preview of the Relay42 Insights module, in pre-beta version Key capabilities of the Relay42 Insights module include: Deep insights into customer behaviors: With the Relay42 Insights module, marketers can ask unlimited questions about their data and gain a deeper understanding of how to serve their customers more effectively. Simplicity with AI-powered querying: Marketers can use artificial intelligence to query their data using natural language search, reducing the reliance on data scientists. Us

Metasphere Labs Announces X Spaces Event on the Topic of Green Bitcoin Mining and Sound Money for Sustainability11.6.2024 10:30:00 CEST | Press release

VANCOUVER, British Columbia, June 11, 2024 (GLOBE NEWSWIRE) -- Metasphere Labs Inc. (formerly Looking Glass Labs Ltd., "Metasphere Labs" or the "Company") (Cboe Canada: LABZ) (OTC: LABZF) (FRA: H1N) is thrilled to announce an engaging Twitter Spaces event on Green Bitcoin mining, energy markets, and sustainability on July 3, 2024 at 2 p.m. ET. Follow us on X at MetasphereLabs for updates and to join the event. What We'll Discuss Bitcoin Mining Basics: Understand the fundamentals of Bitcoin mining.Energy Market Dynamics: Explore how Bitcoin mining interacts with energy markets.Sustainable Innovations: Learn about our efforts to promote sustainability in Bitcoin mining.Sound Money: Discover how tamper-proof currency can enhance stability.Efficient Payment Rails: See how fast, neutral payment systems support humanitarian projects.Carbon Footprint: Compare Bitcoin's environmental impact with traditional banking. "We're excited to host this event and dive into the critical topics of Bitcoin

HiddenA line styled icon from Orion Icon Library.Eye